Compare Novo Nordisk A/S (NVO) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ishares Msci Thailand Etf — how do they compare? Novo Nordisk A/S trades at $46.76 (market cap $207.31B), while Ishares Msci Thailand Etf trades at $72.91. The key difference: Novo Nordisk A/S pays a 3.76% dividend while Ishares Msci Thailand Etf pays none, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | THD | |
|---|---|---|
Market Cap | $207.31B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $75.05 |
52-Week Low | $35.29 | $56.41 |
Enterprise Value | $222.02B | — |
Dividend Yield | 3.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
THD trades at $73.63, up 1.03% for the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock has shown strong performance, driven by exposure to AI hardware plays like Delta Electronics, contributing to its 38% total returns over the past year, as noted by Seeking Alpha on July 9, 2026. A dividend of $1.71 is scheduled for June 2026, adding income potential.
Outlook remains positive due to AI-driven growth, but risks include vulnerability to semiconductor sector volatility and foreign capital outflows from Asian equities. Investors should weigh the bullish technicals against macroeconomic uncertainties in the region for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
